Procyrion bags $30M to push heart failure pump through the clinic

Procyrion developed the Aortix device for patients who don’t respond to heart failure drugs but aren’t sick enough to warrant surgery, such as a heart transplant. (Procyrion)

Procyrion has topped off its coffers with a $30 million series D, which will advance its heart failure pump through a pilot study and toward a pivotal trial. The pump is designed for patients with cardiorenal syndrome, that is, patients with heart failure who are also losing kidney function. 

“Of the more than 1 million patients per year in the U.S. admitted to the hospital with acute decompensated heart failure, 25-30% also have worsening renal function. These are typically the most difficult to treat patients with high mortality and rehospitalization rates. Today there is a major gap in effective therapies that are available to treat these critically ill patients,” said Procyrion President and CEO Eric Fain, M.D., in a statement. 

Procyrion developed the Aortix device for patients who don’t respond to heart failure drugs but aren’t sick enough to warrant surgery, such as a heart transplant or the implantation of a left ventricular assist device—a large, mechanical heart pump. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: A smart toilet seat to detect heart failure? 

Thinner than a pencil, Aortix is delivered through a catheter to a part of the aorta between the heart and the renal arteries. Here, it reduces afterload—the pressure against which the heart must work to pump blood out—requiring the heart to do less work and helping it rest. At the same time, it boosts blood flow to the kidneys, which increases urine output and cuts fluid overload. 

“The Aortix device is uniquely designed and positioned in the body to simultaneously decrease the workload of the heart and improve kidney function. These funds will allow us to make significant advances in our program, in particular, allowing us to assess the Aortix system’s ability to decongest cardiorenal patients in our pilot study,” Fain said in the statement. 

RELATED: Procyrion raises $10M to get minimally invasive mini heart pump in the clinic 

Fain, a veteran of St. Jude Medical, joined Procyrion last July after the devicemaker’s 2017 acquisition by Abbott Medical. He followed fellow St. Jude/Abbott alum Elisabeth Neely, who oversaw global regulatory affairs at St. Jude and then filled that role for Abbott’s cardiac arrhythmias and heart failure unit. Neely now heads up clinical and regulatory affairs at Procyrion. 

The latest round brings Procyrion’s total to more than $59 million. Bluebird Ventures led the round, with Fannin Partners, Scientific Health Development and the state of Texas also pitching in. The Houston-based company picked up $16 million in series C funding early last year, which came after a $10 million B round in 2015.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.